COSTA MESA, Calif., & LAWRENCEVILLE, Ga.–(BUSINESS WIRE)–CareCredit and National Vision Inc. Expand Patient Financing Agreement
Category: Business
rhNGF, der biotechnologisch hergestellte Wirkstoff von Dompé gegen neurotrophe Keratopathie, erhält Orphan-Drug-Status von der Europäischen Arzneimittel-Agentur (EMA)
MAILAND–(BUSINESS WIRE)–Der rekombinante humane Nervenwachstumsfaktor (rhNGF) erhält vom „Ausschuss für Arzneimittel für seltene Leiden“ der Europäischen Arzneimittel-Agentur (EMA) den Orphan-Drug-Status bei der Behandlung der neurotrophen Keratopathie. Das von Dompé entwickelte und biotechnologisch hergestellte Molekül basiert auf den Forschungen der Nobelpreisträgerin Rita Levi Montalcini. NGF ist der erste neurotrophe Faktor, der identifiziert und isoliert werden konnte. Er zählt zu den in
rhNGF, la molécula de biotecnología de Dompé para el tratamiento de la queratitis neurotrófica, recibe la designación de medicamento huérfano de la Agencia Europea de Medicamentos
MILÁN–(BUSINESS WIRE)–La empresa biofarmacéutica Dompé ha anunciado hoy que el Comité de Medicamentos Huérfanos de la Agencia Europea de Medicamentos ha designado oficialmente el factor de crecimiento nervioso humano recombinante (rhNFG) – la molécula de biotecnología en investigación desarrollada por Dompé de acuerdo con los estudios de la premio Nobel Rita Levi-Montalcini – como medicamento huérfano para el tratamiento de la queratitis neurotrófica. NGF es el primer factor neurotrófico que
rhNGF, la molécule de Dompé Biotech pour le traitement de la kératite neurotrophique, obtient la désignation de médicament orphelin de l’Agence européenne du Médicament
MILAN–(BUSINESS WIRE)–La société biopharmaceutique Dompé a annoncé aujourd’hui que le Comité des Médicaments orphelin de l’Agence européenne du Médicament (EMA) a désigné officiellement le facteur de croissance du nerf humain recombinant (rhNGF) – la molécule biotechnologique expérimentale développée par Dompé sur la base des recherches effectuées par la lauréate du Prix Nobel Rita Levi Montalcini – comme étant un médicament orphelin pour le traitement de la kératite neurotrophique. Le facteu
Clearside Biomedical, Inc. Completes $20 Million Series C Financing
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies for diseases of the eye, announces completion of $20 million Series C financing.
rhNGF, the Dompé Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
MILAN–(BUSINESS WIRE)–The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) – the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini – as an orphan drug for the treatment of neurotrophic keratitis. NGF is the first neurotrophic factor to be identified and purified, and represents
rhNGF, la molecola biotecnologica Dompé per la cura della cheratite neurotrofica, designato farmaco orfano dalla European Medicines Agency
MILANO–(BUSINESS WIRE)–L’azienda biofarmaceutica Dompé annuncia che il Comitato per i Farmaci Orfani dell’EMA (European Medicines Agency) ha ufficialmente designato rhNGF, la molecola biotecnologica sperimentale messa a punto dalla ricerca Dompé sulla scorta degli studi del Premio Nobel per la Medicina Rita Levi Montalcini, come farmaco orfano per il trattamento della cheratite neurotrofica. NGF (Nerve Growth Factor) è il primo fattore neurotrofico a essere identificato e purificato e, oggi,
CoreSource and Liazon Partner to Launch TPA Private Exchange Solution
LAKE FOREST, Ill.–(BUSINESS WIRE)–CoreSource, a national health benefits administrator, & Liazon, operator of industry-leading private benefits exchange Bright Choices®, creates a new third-party administrator (TPA) private exchange.
Ophthotech Corporation to Present at the Oppenheimer 26th Annual Healthcare Conference
NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer will present an overview of the Company at the Oppenheimer 26th Annual Healthcare Conference in New York City on December 8, 2015 at 8:35 a.m. ET.
RetroSense Therapeutics to Present at Upcoming Healthcare Conferences
ANN ARBOR, Mich.–(BUSINESS WIRE)–RetroSense Therapeutics Chief Executive Officer Sean Ainsworth will present at the 27th Annual Piper Jaffray Healthcare Conference and the Genetic RX Conference.
ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today…
ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today…
Research and Markets: Choroidal Neovascularization – Pipeline Analysis & Review, H2 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/kxvtp3/choroidal) has announced the addition of the “Choroidal Neovascularization – Pipeline Review, H2 2015” report to their offering. The report, Choroidal Neov…
Research and Markets: Sustained Release Ocular Drug Delivery Systems Market to Reach USD 6.5 Billion by 2025 – Market Analysis and Forecast 2015 – 2025 (2nd edition)
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/sz483m/sustained_release) has announced the addition of the “Sustained Release Ocular Drug Delivery Systems, 2015 – 2025 (2nd edition)” report to their offering. …
Largest Prospective Study Evaluating the Effect of Vigabatrin on Vision
PHILADELPHIA–(BUSINESS WIRE)–The largest prospective study evaluating the effect of vigabatrin on vision will be available to view at the annual meeting of the American Epilepsy Society (AES) in Philadelphia.
Ocular Therapeutix™ to Present at the Piper Jaffray 27th Annual Healthcare Conference
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President, Chief Executive Officer and Chairman, will participate in a fireside chat presentation at the Piper Jaffray 27th Annual Healthcare Conference on Wednesday, December 2, 2015 at 9:30 a.m. ET at The New York Palace Hotel in New York C
Ocular Therapeutix™ Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today enrollment of the first patients in a second Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA™ (sustained release dexamethasone), 0.4mg Intracanalicular Depot for the treatment of allergic conjunctivitis. DEXTENZA is a product candidate administer
Inotek Pharmaceuticals to Present at the Piper Jaffray 27th Annual Healthcare Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals to Present at the Piper Jaffray 27th Annual Healthcare Conference
Second Sight to Present at Piper Jaffray 27th Annual Healthcare Conference
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, announced today that Will McGuire, President and Chief Executive Officer, will present at the Piper Jaffray 27th Annual Healthcare Conference as follows: Date: Wednesday, December 2, 2015 Time: 3:00 p.m. EST Location: Lotte New York Palace
Watch the latest episode of BizWireTV from Business Wire
NEW YORK–(BUSINESS WIRE)–Watch the latest episode of BizWireTV from Business Wire